Xiang, Chunjie
Sun, Yixuan
Luo, Yong
Xie, Cong
Huang, Weikun
Sun, Zilin
Jones, Karen L.
Horowitz, Michael http://orcid.org/0000-0002-0942-0306
Rayner, Christopher K. http://orcid.org/0000-0002-5527-256X
Ma, Jianhua http://orcid.org/0000-0001-9383-2559
Wu, Tongzhi http://orcid.org/0000-0003-1656-9210
Funding for this research was provided by:
National Natural Science Foundation of China (81870561)
Postgraduate Research & Practice Innovation Program of Jiangsu Province
Article History
Received: 26 November 2023
Revised: 6 February 2024
Accepted: 8 February 2024
First Online: 8 April 2024
Competing interests
: K.L.J. is a shareholder with Glyscend. M.H. has participated in advisory boards and/or symposia for Sanofi, Eli Lilly, and Inova, and has received honoraria for this activity. He is a shareholder with Satiogen and Glyscend. C.K.R. has received research funding from AstraZeneca, Merck Sharp & Dohme, Eli Lilly, Novartis, and Sanofi, has participated in advisory boards for Allergan and Glyscend, and has received honoraria for this activity. T.W. has received travel support from Novartis and Sanofi and research funding from Novartis and AstraZeneca. The remaining authors have no personal or financial conflict of interest to declare.
: The protocol was approved by the Human Ethics Committee of Nanjing First Hospital (KY20220124-08) and was prospectively registered on a clinical trials database (NCT05284344).